ケサルピニア・ボンドゥクの低血糖効果 (L). ストレプトゾトシン誘発糖尿病のラットにおけるRoxb葉の抽出物
Ami Febriza1, Anisah Zahrah2, Nurul Andini3
1Department of Physiology, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. amifebriza@med.unismuh.ac.id.
Pediatric endocrinology, diabetes, and metabolism
|February 16, 2026
まとめ
Caesalpinia bonducの葉のエキスは,血糖を効果的に低下させ,糖尿病のラットの臓を保護します. この天然化合物は,インスリン分泌を高め,抗酸化物質の保護を提供することで,糖尿病管理に有望であることが示されています.
科学分野:
- 薬理学と毒理学について
- 自然製品化学 自然製品化学
- エンドクリノロジー エンドクリノロジー
背景:
- 糖尿病は,新しい治療戦略を必要とする重要な世界的な健康問題です.
- 糖尿病治療のための天然製品の探索は,現在の治療法の限界のために非常に重要です.
研究 の 目的:
- Caesalpinia bonduc葉のエキスの低血糖および臓保護効果を調査する.
- ストレプトゾトシン誘発型糖尿病のラットモデルにおけるC. bonducの有効性を評価する.
主な方法:
- 糖尿病のラットは,C. bonducの葉のエキス (150, 200, 400 mg/kg),グリベンクラミド,またはプラセボのさまざまな用量で治療されました.
- 治療後24時間以上,血糖値のモニタリングを行いました.
- 臓組織は組織学的に検査され,植物化学分析が行われました.
主要な成果:
- C. bonduc エクストラクトは,すべての試験用量において,糖尿病のラットにおける血糖値を有意に低下させた.
- 抽出物は,投与量に依存する低血糖効果を示し,投与後6時間後に顕著な減少が観察されました.
- 組織病理学的分析により,治療群で臓の形態の改善と組織損傷の減少が示されました.
結論:
- ケサルピニア・ボンドゥック (Caesalpinia bonduc) の葉のエキスは,著しい低血糖および臓の保護性を持っています.
- エクストラクトに含まれるフラボノイドは,抗酸化物質とインスリン分泌を増強する効果に起因する可能性があります.
- C. bonducのエキスは,糖尿病の補助療法としての可能性を示しており,さらなる臨床研究が必要である.
関連する概念動画
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
608
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
608
Dipeptidyl Peptidase 4 Inhibitors
729
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
729
Oral Hypoglycemic Agents: Glinides
700
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
700
Hormones Regulating Blood Glucose
7.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.1K
Hypoglycemia and Glucagon
1.0K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
696
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
696


